The common interests of health protection and the economy: evidence from scenario calculations of COVID-19 containment policies.

COVID-19 Deaths Economy Integrated simulations Optimal strategy Real-time analysis

Journal

The European journal of health economics : HEPAC : health economics in prevention and care
ISSN: 1618-7601
Titre abrégé: Eur J Health Econ
Pays: Germany
ID NLM: 101134867

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 18 06 2021
accepted: 21 02 2022
pubmed: 21 3 2022
medline: 28 1 2023
entrez: 20 3 2022
Statut: ppublish

Résumé

We develop a novel approach integrating epidemiological and economic models that allows data-based simulations during a pandemic. We examine the economically optimal opening strategy that can be reconciled with the containment of a pandemic. The empirical evidence is based on data from Germany during the SARS-CoV-2 pandemic. Our empirical findings reject the view that there is necessarily a conflict between health protection and economic interests and suggest a non-linear U-shape relationship: it is in the interest of public health and the economy to balance non-pharmaceutical interventions in a manner that further reduces the incidence of infections. Our simulations suggest that a prudent strategy that leads to a reproduction number of around 0.75 is economically optimal. Too restrictive policies cause massive economic costs. Conversely, policies that are too loose lead to higher death tolls and higher economic costs in the long run. We suggest this finding as a guide for policy-makers in balancing interests of public health and the economy during a pandemic.

Identifiants

pubmed: 35306581
doi: 10.1007/s10198-022-01452-y
pii: 10.1007/s10198-022-01452-y
pmc: PMC8934060
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-74

Subventions

Organisme : horizon 2020
ID : 101003480
Organisme : helmholtz-gemeinschaft
ID : Initiative and Networking Fund
Organisme : bundesministerium für bildung und forschung
ID : FKZ: 01KI20102
Organisme : helmholtz-gemeinschaft
ID : ZT-0027

Informations de copyright

© 2022. The Author(s).

Références

Sci Rep. 2021 Feb 18;11(1):4214
pubmed: 33603113
J Health Econ. 2021 Jul;78:102475
pubmed: 34157513
Ann Med Surg (Lond). 2020 Jul 11;57:5-6
pubmed: 32685143
Science. 2020 Jul 10;369(6500):
pubmed: 32414780
Proc Natl Acad Sci U S A. 2020 Dec 22;117(51):32293-32301
pubmed: 33273115
J Econom. 2021 Jan;220(1):23-62
pubmed: 33100476
J Econ Dyn Control. 2022 Jul;140:104318
pubmed: 35125563
JAMA. 2007 Aug 8;298(6):644-54
pubmed: 17684187
Nat Commun. 2020 Aug 26;11(1):4264
pubmed: 32848152
BMC Med. 2021 Jan 28;19(1):32
pubmed: 33504336
Econ Hum Biol. 2022 Nov 8;49:101198
pubmed: 36630757
Science. 2020 Jun 26;368(6498):1422-1424
pubmed: 32461212

Auteurs

Florian Dorn (F)

ifo Institute - Leibniz Institute for Economic Research at the University of Munich, Poschingerstr. 5, 81679, Munich, Germany. dorn@ifo.de.
Economics Department, University of Munich, Ludwigstr. 28, 80539, Munich, Germany. dorn@ifo.de.
CESifo Munich, Poschingerstr. 5, 81679, Munich, Germany. dorn@ifo.de.

Sahamoddin Khailaie (S)

Department of Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Helmholtz Centre for Infection Research, Rebenring 56, 38106, Braunschweig, Germany.

Marc Stoeckli (M)

ifo Institute - Leibniz Institute for Economic Research at the University of Munich, Poschingerstr. 5, 81679, Munich, Germany.
Economics Department, University of Munich, Ludwigstr. 28, 80539, Munich, Germany.

Sebastian C Binder (SC)

Department of Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Helmholtz Centre for Infection Research, Rebenring 56, 38106, Braunschweig, Germany.

Tanmay Mitra (T)

Department of Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Helmholtz Centre for Infection Research, Rebenring 56, 38106, Braunschweig, Germany.

Berit Lange (B)

Department of Epidemiology, Helmholtz Centre for Infection Research (HZI), Inhoffenstr. 7, 38124, Brunswick, Germany.
German Center for Infection Research (DZIF), Inhoffenstr. 7, 38124, Braunschweig, Germany.

Stefan Lautenbacher (S)

ifo Institute - Leibniz Institute for Economic Research at the University of Munich, Poschingerstr. 5, 81679, Munich, Germany.
Economics Department, University of Munich, Ludwigstr. 28, 80539, Munich, Germany.

Andreas Peichl (A)

ifo Institute - Leibniz Institute for Economic Research at the University of Munich, Poschingerstr. 5, 81679, Munich, Germany.
Economics Department, University of Munich, Ludwigstr. 28, 80539, Munich, Germany.
CESifo Munich, Poschingerstr. 5, 81679, Munich, Germany.

Patrizio Vanella (P)

Department of Epidemiology, Helmholtz Centre for Infection Research (HZI), Inhoffenstr. 7, 38124, Brunswick, Germany.
Chair of Empirical Methods in Social Science and Demography, University of Rostock, Ulmenstr. 69, 18057, Rostock, Germany.

Timo Wollmershäuser (T)

ifo Institute - Leibniz Institute for Economic Research at the University of Munich, Poschingerstr. 5, 81679, Munich, Germany.
Economics Department, University of Munich, Ludwigstr. 28, 80539, Munich, Germany.
CESifo Munich, Poschingerstr. 5, 81679, Munich, Germany.

Clemens Fuest (C)

ifo Institute - Leibniz Institute for Economic Research at the University of Munich, Poschingerstr. 5, 81679, Munich, Germany.
Economics Department, University of Munich, Ludwigstr. 28, 80539, Munich, Germany.
CESifo Munich, Poschingerstr. 5, 81679, Munich, Germany.

Michael Meyer-Hermann (M)

Department of Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Helmholtz Centre for Infection Research, Rebenring 56, 38106, Braunschweig, Germany.
Institute for Biochemistry, Biotechnology and Bioinformatics, Technische Universität Braunschweig, Braunschweig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH